Related Breaking News

Eli Lilly and Co. has entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash. The acquisition expands Lilly's animal health business, Elanco, and creates the second-largest animal health company in terms of global revenue.

Novartis Animal Health has a presence in 40 countries and had approximately $1.1 billion in revenues in 2013. Lilly will acquire its nine manufacturing sites, six dedicated R&D facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a pipeline of more than 40 projects in development, and a team of more than 3,000 employees.

The transaction is expected to close by 1Q15, subject to customary closing conditions.

Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important